Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response-guided therapy for hepatitis C genotype 2 and 3 in those with HIV coinfection.

Digestive diseases and sciences - 1 Aug 2014

Win Lay Lay, James Paul, Wong David K

Abstract excerpt

BACKGROUND: Current guidelines recommend that interferon-based treatment of hepatitis C (HCV) genotype 2 or 3 in those with HIV coinfection should be for 48 weeks, especially if HCV PCR remains positive after 4 weeks of treatment. AIM: To examine a single-center experience using response-guided therapy (RGT) using pegylated interferon (PegIFN) and weight-based ribavirin (RBV) for treating HCV genotype 2 or 3 in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Coinfection
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to HIV Infections

Share to Interferons

Share to Ribavirin

Source

Identifiers

PMID: 24846795
DOI: 10.1007/s10620-014-3211-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response-guided therapy for hepatitis C genotype 2 and 3 in those with HIV coinfection.PMID 24846795Read ↗

Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.Semantic proximity Read ↗

Treatment of genotype 2 and genotype 3 hepatitis C virus (HCV) infection in human immunodeficiency virus positive patients.Semantic proximity Read ↗

Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.Semantic proximity Read ↗

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.Semantic proximity Read ↗

Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow.Semantic proximity Read ↗

Treatment of hepatitis C in 2011: what can we expect?Semantic proximity Read ↗

Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV.Semantic proximity Read ↗

Clinical features and therapeutic response in patients with HIV and acute HCV coinfection: a cohort studySemantic proximity Read ↗

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.Semantic proximity Read ↗

Diagnosis, evaluation, and treatment of HIV/HCV coinfection.Semantic proximity Read ↗

Evaluation of the therapeutic response of hepatitis C in coinfected patients (HIV/HCV): a study of cases from a hospital for chronic liver diseases in the Eastern Brazilian Amazon.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.